Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease

• ClinicalTrials.gov Identifier: NCT00606164
• Recruitment Status: Unknown
• First Posted: February 1, 2008
• Last Update Posted: February 1, 2008
• Sponsor: Blanchette Rockefeller Neurosciences Insitute
• Information provided by: Blanchette Rockefeller Neurosciences Insitute

Study Description

Brief Summary:

The main purpose of this study is find out how safe a single dose of bryostatin 1 is in patients with Alzheimer's Disease (AD). This study is also being done 1) to determine how effective a single dose of bryostatin 1 is in the treatment of AD, 2) to find out what happens to bryostatin 1 once it enters the body by measuring the levels of bryostatin 1 in blood, and 3) to measure a substance in the blood (protein kinase C) that may help to better understand how bryostatin 1 works.

Condition or disease	Intervention/treatment	Phase
Alzheimer's Disease	Drug: Bryostatin for Injection; Drug: Placebo	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 9 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Groups, Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Mild to Moderate Alzheimer's Disease
• Study Start Date: April 2008
• Estimated Primary Completion Date: December 2008
• Estimated Study Completion Date: December 2008

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo	Drug: Placebo; A single one-hour intravenous infusion of placebo on Day 1; Other Name: PET (60/30/10) diluent plus sodium chloride for injection
Experimental: 10 ug/m2 Bryostatin	Drug: Bryostatin for Injection; A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1; Other Names: Bryostatin 1; Bryostatin; NSC 339555; CAS No. 83314-01-6
Experimental: 15 ug/m2 Bryostatin	Drug: Bryostatin for Injection; A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1; Other Names: Bryostatin 1; Bryostatin; NSC 339555; CAS No. 83314-01-6

Outcome Measures

Primary Outcome Measures :

1. Adverse Events [ Time Frame: 4-weeks ]
2. Alzheimer's Disease Assessment Scale [ Time Frame: 4-weeks post dose ]
3. Clinician's Interview Based Impression of Change [ Time Frame: 4-weeks post dose ]

Secondary Outcome Measures :

1. Alzheimer's Disease Assessment Scale [ Time Frame: 24, 48, and 72 hrs post dose ]
2. Clinician's Interview Based Impression of Change [ Time Frame: 24, 48, and 72 hrs post dose ]
3. Clinical Dementia Rating Battery [ Time Frame: 24, 48, and 72 hrs post dose and 4-weeks post dose ]
4. Alzheimer's Disease Cooperative Study - Activities of Daily Living [ Time Frame: 24, 48, and 72 hrs post dose and 4-weeks post dose ]
5. Severe Impairment Battery [ Time Frame: 24, 48, and 72 hrs post dose and 4-weeks post dose ]
6. Hopkins Verbal Learning Test-Revised [ Time Frame: 24, 48, and 72 hrs post dose and 4-weeks post dose ]
7. Temperature [ Time Frame: 48 hrs and 4-weeks post dose ]
8. Respiratory rate [ Time Frame: 48 hrs and 4-weeks post dose ]
9. Blood pressure [ Time Frame: 15, 30, and 60 minutes after start of study drug infusion, and at 1, 2, 4, 8, 12, 24, 48, and 72 hrs post infusion and 4-weeks post infusion ]
10. Heart rate [ Time Frame: 15, 30, and 60 minutes after start of study drug infusion, and at 1, 2, 4, 8, 12, 24, 48, and 72 hrs post infusion and 4-weeks post infusion ]
11. Electrocardiogram [ Time Frame: 15, 30, and 60 minutes after start of study drug infusion, and at 1, 2, 4, 8, 12, and 24 hrs post infusion and 4-weeks post infusion ]
12. Physical Exam [ Time Frame: 48 hrs and 4-weeks post dose ]
13. Hematology [ Time Frame: 48 hrs and 4-weeks post dose ]
14. Blood chemistry [ Time Frame: 48 hrs and 4-weeks post dose ]
15. Urinalysis [ Time Frame: 48 hrs and 4-weeks post dose ]
16. Pharmacokinetics [ Time Frame: Blood draws at baseline, during the study drug infusion (15, 30, and 60 minutes after start of infusion), and at 20 minutes, 1 hr, 2 hrs, 6 hrs, 24 hrs, 48 hrs, and 72 hrs post infusion ]
17. Protein kinase C activity (pharmacodynamics) [ Time Frame: Blood draws at baseline, during the study drug infusion (15, 30, and 60 minutes after start of infusion), and at 20 minutes, 1 hr, 2 hrs, 6 hrs, 24 hrs, 48 hrs, and 72 hrs post infusion ]

Eligibility Criteria

• Ages Eligible for Study: 50 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female, age 50 yrs or older. Females must be of non-childbearing potential (surgically sterilized or at least 2 yrs post-menopausal)
• Must have a cognitive deficit present for at least 1 yr & meet DSM-IV-TRTM criteria for AD & meet NINCDS/ADRDA criteria for the presence of probable AD
• Severity of AD must be mild to moderate, documented with a MMSE score of 12-26
• Has a CT scan or MRI scan within the prior 12 months, which is compatible with a diagnosis of probable AD
• Ability to walk, at least with an assistive device
• Vision & hearing sufficient to comply with testing
• Normal cognitive & social functioning prior to onset of dementia
• Consistent caregiver to accompany patient to assessment visits
• Sufficient basic education to be able to complete the cognitive assessments
• Living outside an institution
• Informed consent signed & dated by patient or legal representative
• Has provided written authorization for the use & disclosure of protected health information

Exclusion Criteria:

• Dementia due to any condition other than AD, including vascular dementia (modified Hachinski Ischemic Scale ≥ 5; positive NINDS-AIREN criteria)
• Evidence of clinically significant unstable cardiovascular, renal, hepatic, gastrointestinal, neurological, or metabolic disease within the past 6 months (as determined by medical history, ECG results, chest x-ray, or physical examination)
• Use of any drug within 14 days prior to randomization unless the dose of the drug & the condition being treated have been stable for at least 30 days & are expected to remain stable during the study & neither the drug nor the condition being treated is expected to interfere with the study endpoints
• Any medical or psychiatric condition that may require medication or surgical treatment during the study
• Life expectancy less than 6 months
• Any other screening laboratory values outside the normal ranges that are deemed clinically significant by the investigator
• Use of an investigational drug within 30 days prior to the screening visit or during the entire study
• Significant neurological disease other than AD, including cerebral tumor, Huntington's Disease, Parkinson's Disease, normal pressure hydrocephalus, & other entities
• Major depression according to DSM-IV
• Psychotic episodes requiring hospitalization or antipsychotic therapy for more than 2 weeks within the past 10 yrs, not linked to AD
• Agitation sufficient to preclude participation in this trial
• Alcohol or drug dependence diagnosed within the past 10 yrs
• Epilepsy or anti-epileptic drug therapy
• Abnormal laboratory tests that might point to another etiology for dementia: serum B12, folate, thyroid functions, electrolytes, syphilis serology
• Musculoskeletal diseases that could interfere with assessment
• Acute or poorly controlled medical illness: blood pressure> 180 mmHg systolic or 100 mmHg diastolic; myocardial infarction within 6 months; uncompensated congestive heart failure (NYHA Class III or IV), severe renal, hepatic or gastrointestinal disease that could alter drug pharmacokinetics; blood glucose > 180 mg/dl on repeated testing at entry into study or need for insulin therapy
• Previous randomization in this trial or participation in another investigational trial < 2 months prior to randomization
• Likelihood, according to clinical judgment, of being transferred to a nursing home within 6 months
• Change in dosage of any concomitant antidepressant within 30 days prior to randomization
• Lack of caregiver
• Pregnant or lactating females
• Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedures outlined in this protocol
• HIV positive
• Hepatitis B or C positive
• Concomitant use of medications other than AD or antidepressant medications for which the dose regimens are stabilized for at least 30 days prior to enrollment in study

Contacts and Locations

Locations

United States, West Virginia

Chestnut Ridge Center West Virginia University Department of Behavioral Medicine and Psychiatry

Morgantown, West Virginia, United States, 26505

Contact: Eric Rankin, Ph.D. 304-293-5323 erankin@hsc.wvu.edu

Principal Investigator: James M Stevenson, MD

Sponsors and Collaborators

Blanchette Rockefeller Neurosciences Insitute

Investigators

• Principal Investigator: James M Stevenson, MD; West Virginia University Department of Behavioral Medicine and Psychiatry

More Information

• Responsible Party: Mark A. Cochran, Ph.D./CEO and Executive Director, Blanchette Rockefeller Neurosciences Insitute
• ClinicalTrials.gov Identifier: NCT00606164
• Other Study ID Numbers: BRY-201
• First Posted: February 1, 2008
• Last Update Posted: February 1, 2008
• Last Verified: January 2008

Keywords provided by Blanchette Rockefeller Neurosciences Insitute:

Alzheimer's Disease; bryostatin 1; bryostatin; safety; efficacy; pharmacokinetics; pharmacodynamics; protein kinase C

Additional relevant MeSH terms:

Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders; Bryostatin 1; Adjuvants, Immunologic; Immunologic Factors; Physiological Effects of Drugs; Antineoplastic Agents